Neurocrine Biosciences, Inc.
NBIX
$102.88
-$5.43-5.01%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -20.57% | 99.69% | 49.77% | -70.62% | 77.74% |
| Total Depreciation and Amortization | 9.23% | -10.96% | 17.74% | 8.77% | 3.64% |
| Total Amortization of Deferred Charges | -- | -378.47% | -43.97% | -- | -- |
| Total Other Non-Cash Items | -75.59% | 438.75% | 22.46% | -0.84% | -69.25% |
| Change in Net Operating Assets | 2,043.18% | 105.10% | -173.10% | 41.15% | -216.74% |
| Cash from Operations | 53.48% | 144.58% | -50.42% | 5.51% | -41.75% |
| Capital Expenditure | 9.88% | 30.17% | -3.57% | -107.41% | 28.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -285.98% | 297.59% | 62.10% | 77.70% | -118.95% |
| Cash from Investing | -376.52% | 187.59% | 48.73% | 72.75% | -107.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | -62.12% | 67.09% | -77.40% | 97.46% | 88.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1,198.48% | 109.01% | -519.17% | 97.46% | 88.30% |
| Foreign Exchange rate Adjustments | -200.00% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -155.44% | 181.61% | -276.72% | 440.85% | -131.91% |
